Most Read Articles
3 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 3 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
4 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Multiple myeloma patients show excellent response to stem cell treatment

13 Sep 2020
Scientists fear new regulations would limit the potential of stem cell therapies.

A small set of multiple myeloma (MM) patients will show exceptional response to autologous stem cell transplantation (ASCT) and remain progression-free for years without maintenance therapy, a recent study has found.

“Further studies are needed to pre-emptively identify this subset of patients who may not need aggressive, life-long therapy to maintain disease control, in order to decrease the long-term risk of financial and physical toxicity,” researchers said.

Of the 509 MM patients who received ASCT during the study period, 51 showed excellent long-term response. These patients showed no evidence of disease progression for at least 96 months. However, five were eventually excluded: two received maintenance therapy after transplantation, three patients showed developed smouldering MM.

Overall, 46 patients (median age at diagnosis, 57 years; 61 percent female) were deemed to be exceptional responders to ASCT, yielding a rate of 9 percent. In this group, the median duration of follow-up from diagnosis was 16.2 years.

Most of the exceptional responders (74 percent; n=34) showed complete response or better to ASCT, and another six patients (13 percent) had very good partial response. The poorest response status was achieving a stable disease, which was reported in one patient. The median time to best response after ASCT was 3 months.

At the time of the final haematology assessment, more than half (52 percent; n=24) of the participants were still in remission, and 19 still showed complete response. The median progression-free and overall survival post-ASCT were 13.8 and 19.9 years, respectively.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 3 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
4 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.